AZD4547 is a selective inhibitor of fibroblast growth factor receptors (FGFRs), particularly FGFR1, FGFR2, and FGFR3. It is primarily investigated for its potential in cancer therapy, especially in tumors driven by FGFR signaling pathway abnormalities. This includes certain types of lung, breast, gastric, and bladder cancers where FGFR gene amplifications or mutations contribute to tumor growth and progression. By blocking FGFR activity, AZD4547 interferes with downstream signaling pathways such as MAPK and PI3K/AKT, which are involved in cell proliferation, survival, and angiogenesis. This leads to reduced tumor growth and, in some cases, tumor regression in preclinical models. AZD4547 has been used in clinical trials to evaluate its efficacy and safety in patients with advanced solid tumors harboring FGFR alterations. It is also being studied in combination with other anticancer agents to overcome resistance and improve therapeutic outcomes. Due to its targeted mechanism, AZD4547 represents a promising approach in personalized oncology, where treatment is tailored based on the genetic profile of the tumor.